Quantum Drug Discovery and the Path to Advantage with Sabrina Maniscalco

Why This Episode MattersSabrina Maniscalco is one of the few people in quantum who has lived the full arc: two decades of academic work on open quantum systems and non-Markovian noise at Palermo, Turku, Edinburgh, and Helsinki, followed by founding Algorithmiq with three of her former researchers after an early Qiskit Camp. That trajectory matters now because Algorithmiq just had a landmark stretch — sole winner of the $2M Wellcome Leap Q4Bio prize for a quantum-enabled cancer drug discovery workflow, an €18M Series B, a global HQ move to Milan, and its Tensor Network Error Mitigation (TEM) function landing in IBM's Qiskit Functions catalog.If you're trying to make sense of where quantum software actually creates value before fault tolerance arrives — and what a credible "trajectory to advantage" looks like when paired with real clients in life sciences — this is a grounded, technically specific conversation with someone building it.EPISODE SPONSORThis episode is brought to you by Outshift, Cisco's incubation engine. The need for computational power is rapidly increasing in every sector. From drug discovery to material innovation to complex financial modeling, classical systems are reaching their absolute limits. It's time for a paradigm shift. The answer is a scalable quantum network, built on open standards and vendor-agnostic architecture. By uniting distributed quantum devices, you unlock limitless computational power.Learn more about the Cisco Universal Quantum Switch at Outshift.com.Go deeper with the blog post The switch that quantum networking has been waiting for.What We Get IntoWhy a background in open quantum systems and non-Markovian noise turned out to be unusually well-suited to running algorithms on noisy near-term hardwareThe actual science behind the Q4Bio winning workflow: simulating excited-state dynamics of a photosensitizer drug already in Phase II clinical trials, on up to 100 qubitsHow quantum-boosted DMRG works — and why it gives you a built-in benchmark against the best classical method via the bond dimensionThe tradeoff Sabrina would and wouldn't make between more qubits and lower noise, and why neutral atoms' slower sampling rates matter for chemistryWhy even fault-tolerant algorithms like quantum phase estimation still depend on getting state initialization and measurement rightAlgorithmiq's two-product structure: the Digital Quantum Interface (hardware-agnostic infrastructure) and the life sciences application frameworkHow methods built for chemistry are now opening doors into optimization and GenAI — and why that direction emerged from the work, not from a strategy deckWhat the move from Helsinki to Milan signals about the European quantum ecosystem and Algorithmiq's commercial scale-upHow an active learning pipeline is already proposing novel drug variants for synthesis in Prof. Sherri McFarland's labResources & LinksGuest & CompanyAlgorithmiq — The company Sabrina co-founded with Guillermo García-Pérez, Matteo Rossi, and Boris Sokolov; quantum software for life sciences and chemistry.Sabrina Maniscalco — University of Helsinki Research Portal — Publication record covering open quantum systems, non-Markovian dynamics, and quantum information.Sabrina Maniscalco — AI for Good Bio — Consolidated bio covering academic roles and advisory positions, including IQOQI Austria and CERN's Quantum Technology Initiative.The Q4Bio WinAlgorithmiq Wins $2M Wellcome Leap Q4Bio Prize — Company announcement detailing the photodynamic therapy workflow.Wellcome Leap — Q4Bio Prize Announcement — Funder's perspective on finalists and criteria.IBM Qua